Search Results - "DICKLER, Maura N"

Estrogen Receptor‐Positive Breast Cancer: Exploiting Signaling Pathways Implicated in Endocrine Resistance by Brufsky, Adam M., Dickler, Maura N.

“…Advancements in molecular profiling and endocrine therapy (ET) have led to more focused clinical attention on precision medicine. These advances have expanded…”
Get full text

The Role of CDK4/6 Inhibition in Breast Cancer by Murphy, Conleth G., Dickler, Maura N.

“…Imbalance of the cyclin D and cyclin‐dependent kinase (CDK) pathway in cancer cells may result in diversion away from a pathway to senescence and toward a more…”
Get full text

Endocrine resistance in hormone-responsive breast cancer: mechanisms and therapeutic strategies by Murphy, Conleth G, Dickler, Maura N

“…The majority of breast cancers may be considered hormone responsive due to expression of hormone receptors (HR+). Although endocrine therapy is always…”
Get full text

Endocrine Therapy for Hormone Receptor-Positive Metastatic Breast Cancer: American Society of Clinical Oncology Guideline by Rugo, Hope S, Rumble, R Bryan, Macrae, Erin, Barton, Debra L, Connolly, Hannah Klein, Dickler, Maura N, Fallowfield, Lesley, Fowble, Barbara, Ingle, James N, Jahanzeb, Mohammad, Johnston, Stephen R D, Korde, Larissa A, Khatcheressian, James L, Mehta, Rita S, Muss, Hyman B, Burstein, Harold J

“…To develop recommendations about endocrine therapy for women with hormone receptor (HR) -positive metastatic breast cancer (MBC). The American Society of…”
Get full text

PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D by Toska, Eneda, Osmanbeyoglu, Hatice U., Castel, Pau, Chan, Carmen, Hendrickson, Ronald C., Elkabets, Moshe, Dickler, Maura N., Scaltriti, Maurizio, Leslie, Christina S., Armstrong, Scott A., Baselga, José

“…Activating mutations in PIK3CA, the gene encoding phosphoinositide-(3)-kinase α (PI3Kα), are frequently found in estrogen receptor (ER)–positive breast cancer…”
Get full text

A Phase II Trial of Erlotinib in Combination with Bevacizumab in Patients with Metastatic Breast Cancer by DICKLER, Maura N, RUGO, Hope S, GILEWSKI, Teresa A, BROMBERG, Jacqueline F, SEIDMAN, Andrew D, D'ANDREA, Gabriella M, MOASSER, Mark M, MELISKO, Michele, PARK, John W, DANCEY, Janet, NORTON, Larry, HUDIS, Clifford A, EBERLE, Carey A, BROGI, Edi, CARAVELLI, James F, PANAGEAS, Katherine S, BOYD, Jeff, YEH, Benjamin, LAKE, Diana E, DANG, Chau T

“…Purpose: To evaluate the efficacy and toxicity of erlotinib plus bevacizumab in patients with metastatic breast cancer (MBC), targeting the epidermal growth…”
Get full text

MONARCH 1, A Phase II Study of Abemaciclib, a CDK4 and CDK6 Inhibitor, as a Single Agent, in Patients with Refractory HR + /HER2 - Metastatic Breast Cancer by Dickler, Maura N, Tolaney, Sara M, Rugo, Hope S, Cortés, Javier, Diéras, Véronique, Patt, Debra, Wildiers, Hans, Hudis, Clifford A, O'Shaughnessy, Joyce, Zamora, Esther, Yardley, Denise A, Frenzel, Martin, Koustenis, Andrew, Baselga, José

“…The phase II MONARCH 1 study was designed to evaluate the single-agent activity and adverse event (AE) profile of abemaciclib, a selective inhibitor of CDK4…”
Get full text

Maximizing the Potential of Bevacizumab in Cancer Treatment by Bergsland, Emily, Dickler, Maura N.

“…Learning Objectives After completing this course, the reader will be able to: Identify the major side effects of bevacizumab treatment. Describe the drug…”
Get full text

Feasibility Trial of Letrozole in Combination With Bevacizumab in Patients With Metastatic Breast Cancer by TRAINA, Tiffany A, RUGO, Hope S, SEIDMAN, Andrew D, FORNIER, Monica, LAKE, Diana, CHAU DANG, ROBSON, Mark, THEODOULOU, Maria, FLOMBAUM, Carlos D, NORTON, Larry, HUDIS, Clifford A, DICKLER, Maura N, CARAVELLI, James F, PATIL, Sujata, YEH, Benjamin, MELISKO, Michele E, PARK, John W, GENEUS, Stephanie, PAULSON, Matthew, GROTHUSEN, Jill

“…Preclinical models suggest that the use of anti-vascular endothelial growth factor (anti-VEGF) therapy with antiestrogens may prevent or delay the development…”
Get full text

Double PIK3CA mutations in cis increase oncogenicity and sensitivity to PI3Kα inhibitors by Vasan, Neil, Razavi, Pedram, Johnson, Jared L, Shao, Hong, Shah, Hardik, Antoine, Alesia, Ladewig, Erik, Gorelick, Alexander, Lin, Ting-Yu, Toska, Eneda, Xu, Guotai, Kazmi, Abiha, Chang, Matthew T, Taylor, Barry S, Dickler, Maura N, Jhaveri, Komal, Chandarlapaty, Sarat, Rabadan, Raul, Reznik, Ed, Smith, Melissa L, Sebra, Robert, Schimmoller, Frauke, Wilson, Timothy R, Friedman, Lori S, Cantley, Lewis C, Scaltriti, Maurizio, Baselga, José

“…Activating mutations in are frequent in human breast cancer, and phosphoinositide 3-kinase alpha (PI3Kα) inhibitors have been approved for therapy. To…”
Get full text

Sexual health needs and educational intervention preferences for women with cancer by Stabile, Cara, Goldfarb, Shari, Baser, Raymond E., Goldfrank, Deborah J., Abu-Rustum, Nadeem R., Barakat, Richard R., Dickler, Maura N., Carter, Jeanne

“…Purpose To assess sexual/vaginal health issues and educational intervention preferences in women with a history of breast or gynecologic cancer. Methods…”
Get full text

Mutation Detection in Patients With Advanced Cancer by Universal Sequencing of Cancer-Related Genes in Tumor and Normal DNA vs Guideline-Based Germline Testing by Mandelker, Diana, Zhang, Liying, Kemel, Yelena, Stadler, Zsofia K, Joseph, Vijai, Zehir, Ahmet, Pradhan, Nisha, Arnold, Angela, Walsh, Michael F, Li, Yirong, Balakrishnan, Anoop R, Syed, Aijazuddin, Prasad, Meera, Nafa, Khedoudja, Carlo, Maria I, Cadoo, Karen A, Sheehan, Meg, Fleischut, Megan H, Salo-Mullen, Erin, Trottier, Magan, Lipkin, Steven M, Lincoln, Anne, Mukherjee, Semanti, Ravichandran, Vignesh, Cambria, Roy, Galle, Jesse, Abida, Wassim, Arcila, Marcia E, Benayed, Ryma, Shah, Ronak, Yu, Kenneth, Bajorin, Dean F, Coleman, Jonathan A, Leach, Steven D, Lowery, Maeve A, Garcia-Aguilar, Julio, Kantoff, Philip W, Sawyers, Charles L, Dickler, Maura N, Saltz, Leonard, Motzer, Robert J, O’Reilly, Eileen M, Scher, Howard I, Baselga, José, Klimstra, David S, Solit, David B, Hyman, David M, Berger, Michael F, Ladanyi, Marc, Robson, Mark E, Offit, Kenneth

“…IMPORTANCE: Guidelines for cancer genetic testing based on family history may miss clinically actionable genetic changes with established implications for…”
Get full text

Increased chemotherapy-induced ovarian reserve loss in women with germline BRCA mutations due to oocyte deoxyribonucleic acid double strand break repair deficiency by Oktay, Kutluk H., Bedoschi, Giuliano, Goldfarb, Shari B., Taylan, Enes, Titus, Shiny, Palomaki, Glenn E., Cigler, Tessa, Robson, Mark, Dickler, Maura N.

“…To assess whether woman who have BRCA mutations (WBM) experience more declines in ovarian reserve after chemotherapy treatment, as it induces oocyte death by…”
Get full text

Feasibility, safety, and efficacy of aerobic training in pretreated patients with metastatic breast cancer: A randomized controlled trial by Scott, Jessica M., Iyengar, Neil M., Nilsen, Tormod S., Michalski, Meghan, Thomas, Samantha M., Herndon, James, Sasso, John, Yu, Anthony, Chandarlapaty, Sarat, Dang, Chau T., Comen, Elizabeth A., Dickler, Maura N., Peppercorn, Jeffrey M., Jones, Lee W.

“…BACKGROUND The investigation of exercise training in metastatic breast cancer has received minimal attention. This study determined the feasibility and safety…”
Get full text

A phase IIA trial of acupuncture to reduce chemotherapy-induced peripheral neuropathy severity during neoadjuvant or adjuvant weekly paclitaxel chemotherapy in breast cancer patients by Bao, Ting, Seidman, Andrew D., Piulson, Lauren, Vertosick, Emily, Chen, Xi, Vickers, Andrew J., Blinder, Victoria S., Zhi, Wanqing I., Li, Qing, Vahdat, Linda T., Dickler, Maura N., Robson, Mark E., Mao, Jun J.

“…Chemotherapy-induced peripheral neuropathy (CIPN) is a common and potentially dose-limiting side-effect of neurotoxic chemotherapy for cancer patients. We…”
Get full text

Molecular Imaging of Biomarkers in Breast Cancer by Ulaner, Gary A, Riedl, Chris C, Dickler, Maura N, Jhaveri, Komal, Pandit-Taskar, Neeta, Weber, Wolfgang

“…The success of breast cancer therapy is ultimately defined by clinical endpoints such as survival. It is valuable to have biomarkers that can predict the most…”
Get full text

Phase III Trial Evaluating Letrozole As First-Line Endocrine Therapy With or Without Bevacizumab for the Treatment of Postmenopausal Women With Hormone Receptor-Positive Advanced-Stage Breast Cancer: CALGB 40503 (Alliance) by Dickler, Maura N, Barry, William T, Cirrincione, Constance T, Ellis, Matthew J, Moynahan, Mary Ellen, Innocenti, Federico, Hurria, Arti, Rugo, Hope S, Lake, Diana E, Hahn, Olwen, Schneider, Bryan P, Tripathy, Debasish, Carey, Lisa A, Winer, Eric P, Hudis, Clifford A

“…To investigate whether anti-vascular endothelial growth factor therapy with bevacizumab prolongs progression-free survival (PFS) when added to first-line…”
Get full text

Twenty‐one–gene recurrence score assay in BRCA‐associated versus sporadic breast cancers: Differences based on germline mutation status by Shah, Payal D., Patil, Sujata, Dickler, Maura N., Offit, Kenneth, Hudis, Clifford A., Robson, Mark E.

“…BACKGROUND Biological differences between BRCA‐associated breast cancer and sporadic breast cancer may warrant different adjuvant chemotherapy (ACRx)…”
Get full text

Phase II Study of Taselisib (GDC-0032) in Combination with Fulvestrant in Patients with HER2-Negative, Hormone Receptor-Positive Advanced Breast Cancer by Dickler, Maura N, Saura, Cristina, Richards, Donald A, Krop, Ian E, Cervantes, Andrés, Bedard, Philippe L, Patel, Manish R, Pusztai, Lajos, Oliveira, Mafalda, Cardenas, Alison K, Cui, Na, Wilson, Timothy R, Stout, Thomas J, Wei, Michael C, Hsu, Jerry Y, Baselga, José

“…This single-arm, open-label phase II study evaluated the safety and efficacy of taselisib (GDC-0032) plus fulvestrant in postmenopausal women with locally…”
Get full text

Cancer and Fertility Program Improves Patient Satisfaction With Information Received by Kelvin, Joanne F, Thom, Bridgette, Benedict, Catherine, Carter, Jeanne, Corcoran, Stacie, Dickler, Maura N, Goodman, Karyn A, Margolies, Allison, Matasar, Matthew J, Noy, Ariela, Goldfarb, Shari B

“…A cancer and fertility program was established at a large cancer center to support clinicians in discussing treatment-related fertility risks and fertility…”
Get full text